EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
(NASDAQ: EYPT) Delayed: 13.03 +0.53 (4.24%)
Previous Close $12.50    52 Week High $ 
Open $12.67    52 Week Low $ 
Day High $13.05    P/E N/A 
Day Low $12.61    EPS $ 
Volume 1,093,548